These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16414909)

  • 1. Safety of Sculptra: a review of clinical trial data.
    Engelhard P; Humble G; Mest D
    J Cosmet Laser Ther; 2005 Dec; 7(3-4):201-5. PubMed ID: 16414909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring.
    Lam SM; Azizzadeh B; Graivier M
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):55S-63S. PubMed ID: 16936545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV facial lipoatrophy: causes and treatment options.
    Jones D
    Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients.
    Borelli C; Kunte C; Weisenseel P; Thoma-Greber E; Korting HC; Konz B
    Skin Pharmacol Physiol; 2005; 18(6):273-8. PubMed ID: 16113597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy].
    Thiéry G; Coulet O; Adam S; Guyot L
    Rev Stomatol Chir Maxillofac; 2008 Apr; 109(2):103-5. PubMed ID: 18374957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy.
    Sturm LP; Cooter RD; Mutimer KL; Graham JC; Maddern GJ
    AIDS Patient Care STDS; 2009 Sep; 23(9):699-714. PubMed ID: 19673594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study.
    Levy RM; Redbord KP; Hanke CW
    J Am Acad Dermatol; 2008 Dec; 59(6):923-33. PubMed ID: 19022099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caring for HIV-positive and aging patients with associated facial lipoatrophy.
    Esch P
    Plast Surg Nurs; 2006; 26(1):17-23. PubMed ID: 16543853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid.
    Mest DR; Humble GM
    Aesthetic Plast Surg; 2009 Jul; 33(4):654-6. PubMed ID: 18704558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing poly-L-lactic acid use.
    Lowe NJ
    J Cosmet Laser Ther; 2008 Mar; 10(1):43-6. PubMed ID: 18330797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facial enhancement and the European experience with Sculptra (poly-l-lactic acid).
    Vleggaar D; Bauer U
    J Drugs Dermatol; 2004; 3(5):542-7. PubMed ID: 15552606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly-L-lactic acid as a facial filler.
    Sterling JB; Hanke CW
    Skin Therapy Lett; 2005 Jun; 10(5):9-11. PubMed ID: 15986083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
    Mest DR; Humble GM
    Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of facial lipoatrophy via autologous fat transfer.
    Cohen G; Treherne A
    J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
    Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
    Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies.
    Barton SE; Engelhard P; Conant M
    Int J STD AIDS; 2006 Jul; 17(7):429-35. PubMed ID: 16820069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soft-tissue augmentation and the role of poly-L-lactic acid.
    Vleggaar D
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):46S-54S. PubMed ID: 16936544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.